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Abstract  
Purpose 
The relationship between cancer screening activities in Europe and the health systems in 
which they are embedded varies, with some screening programmes organised largely 
separately, and others using existing health service staff and facilities. Whatever the precise 
arrangements, the opportunity for screening to achieve health gain depends on many 
elements interacting within and beyond the health system, from an accurate register 
identifying the target population to a means to ensure and monitor follow up.  
Method 
A conjoint analysis was undertaken with 66 cancer screening experts from 31 countries 
taking part in EU-TOPIA (Towards improved screening for breast, cervical and colorectal 
cancer in all of Europe) to identify priorities for an effective screening programme, taking a 
whole system perspective. Ten attributes, each with two levels, were derived from a review 
of the literature and consultation with experts in cancer screening. Statistical software 
generated 12 profiles that were ranked by respondents and analysed using standard 
conjoint analysis.  
Findings and conclusion 
The most important attributes were having up-to-date and evidence-based guidelines, 
followed by mechanisms for systematic monitoring of screening uptake, having a population 
register covering all of the eligible population and monitoring long-term outcomes. In 
discussions about the results, participants argued that quality assurance and adherence to 
guidelines were important, even though they generated low scores in the experiment. This 
difference may be due some attributes being inter-related, more wide-ranging or the 
sequential nature of establishing an effective screening programme, with guidelines being 
the first stage of the process. 
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Introduction  
What makes an effective cancer screening programme? This is a key question for 
researchers and policy makers aiming to improve cancer screening programmes in Europe. 
Cancer screening activities in Europe are embedded within wider health systems but their 
relationships with them varies. Some are organised largely separately, with their own staff 
and facilities, and others using existing resources, as examinations are undertaken, either 
opportunistically or within an organised framework, by gynaecologists and other physicians 
in their own premises. However, whatever the precise arrangements, the opportunity for 
screening to achieve health gain depends on the interaction of many elements within and 
beyond the health system, from an accurate register identifying the target population to a 
means to ensure and monitor follow up, such as linkage to a cancer registry. Consequently, 
those responsible for cancer screening must look beyond the aspects of the process over 
which they have direct control. 
The EU-TOPIA project (Towards improved screening for breast, cervical and colorectal 
cancer in all of Europe) aims to optimise screening in Europe1. Although the European 
Council issued comprehensive recommendations for breast, cervical and colorectal cancer 
screening in Europe, performance indicators show that there is still a need to develop more 
effective population-based screening programs in Europe2-5. As demonstrated in previous 
studies by the authors6-8 there remain many barriers to effective cancer screening within 
broader health systems and beyond. Defining an effective screening programme is one step 
in the process towards improvement and overcoming these system barriers.  
Given the growing burden of healthcare and the limited resources available, there is a need 
for researchers and policy makers to prioritise areas for attention. Choice experiments offer 
a means to identify the importance attributed to different factors affecting healthcare delivery 
whilst taking account of the real life trade-offs that need to be made in an environment of 
limited resources. Previous experiments of this type of methodology have been used to 
assess patient preferences for cancer screening, thereby informing the design and operation 
of services9,10. This focus reflects the preponderance, in the literature on barriers to effective 
screening, of barriers to individual participation rather than service or system level barriers (a 
systematic review by the authors has been submitted for publication elsewhere). This 
experiment aims to readdress the balance of evidence by investigating the attitudes and 
beliefs of those responsible for the organisation of screening programmes at a national and 
regional level. 
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Methods 
We used a conjoint analysis methodology incorporating a single ranking exercise. Our 
methodology was informed by a review of the available literature11-14, a systematic literature 
review of discrete choice methods15 and insights gained from prior studies conducted by the 
authors16-18.  
As shown in Figure 1, the conjoint methodology included four key stages. The first stage is 
to identify a list of key attributes that we believe, based on the available evidence, to be 
essential for an effective screening programme. For example, as will be described later, one 
attribute of a screening programme is that it uses a register that includes the entire 
population. Each attribute has a series of levels. Using the same example, we selected only 
two possible levels, yes, such a register is used, or no, none is used. It would be possible to 
have had more levels, for example with three levels, a register that covered 100%, 70-99%, 
and less than 70%. However, we had no sound basis for choosing these thresholds. The 
second stage is to generate profiles of screening programmes, each specifying one level for 
each attribute. Thus, in the example above, some profiles would include a register covering 
the entire population and others would not. Each would also contain similar information on all 
the other attributes. Even with a small number of attributes and levels, the number of 
possible combinations is enormous, so we use the orthoplan routine in the SPSS software 
package19 to generate a smaller sub-sample of all possible profiles. The resulting profiles 
have two important characteristics. They are balanced, that each level in each attribute 
appears the same number of times, and are orthogonal, so that every pair of levels, where 
one is from one attribute and one from another attribute, appear the same number of times 
in the design. These characteristics are necessary for the final stage. Before that, in the third 
stage, individuals are asked to rank all profiles from the best to worst cancer screening 
programmes. The characteristics of the profiles that have been generated in this way, 
combined with the ranking by participants, are then combined in the fourth and final stage, 
using the conjoint routine in SPSS, to calculate weights relating to the importance placed on 
each attribute (‘utility’)20-23.  
Following the conjoint experiment, we engaged in a discussion of the results with 
participants in the study in order to gain a better understanding of their meaning and 
implications.  
Establishing the attributes 
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Following our literature reviews, we used three key papers as a basis for establishing a list of 
key attributes and potential levels to use in the conjoint exercise. Firstly, the European 
Commission report on the implementation of the Council recommendation on cancer 
screening (reprint May 2017)2 identified the following essential stages of a screening 
programme: information and invitation of the target population; performing the screening 
test; assessment or follow-up of abnormalities detected; referral for diagnostic confirmation 
and treatment; and treatment, if applicable. Secondly, Anttila et al. 201524 described as 
essential the following phases of a programme: identification and personal invitation of each 
eligible individual; performance of the screening test - examination or procedure; diagnostic 
work-up of people with detected abnormalities; and when indicated, treatment, surveillance 
and aftercare. Thirdly, Lynge et al. 201225 described essential phases of the implementation 
of a screening programme as : before planning, planning, feasibility, pilot, roll-out, running 
programme, and sustainability. From these papers, we collated a list of attributes and then 
prioritised 13 of them based on knowledge obtained from previous work conducted as part of 
the EU-TOPIA project. 
We conducted a pilot with five healthcare researchers in London to assess the feasibility of 
the required task using the initial list of attributes. We asked the researchers to do a ranking 
exercise with a set of 27 profiles generated from the 13 attributes and we then discussed 
their experience in a qualitative manner. The researchers were not experts in cancer 
screening but this allowed us to ensure the feasibility of the exercise and provide feedback 
on the meaningfulness of the descriptions.  
The qualitative feedback from the pilot indicated that the large number of profiles we initially 
considered was excessive as it was impractical to rank them in one exercise from best to 
worst. Consequently, we reduced the numbers of attributes from 13 to 10 and minimised the 
number of levels to two per attribute (as shown in Table 1) so that respondents had 12 
profiles to rank, which was deemed manageable by those involved in the pilot.   
The qualitative assessment of the pilot also suggested that a refinement of the attribute 
descriptions was required to facilitate the exercise. The initial short descriptions were 
considered to be open to interpretation.  We added long descriptions to add clarification 
(Table 2).  
The descriptions of the attributes and levels were then reviewed by a team of experts in 
cancer screening programmes from six European countries taking part in the EU-TOPIA 
project to ensure external validity.  
Generation of profiles 
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We created a data file listing the ten attributes and two alternative levels. We used a 
standard SPSS conjoint syntax for orthogonal design (orthoplan)19-22 to generate a series of 
profiles combining these attributes and levels, to generate a series of 12 profiles. Listing all 
combinations would generate a large number of profiles. Thus, the software generated just 
enough combinations that allow the authors to calculate the weights that participants give to 
each attribute, based on their rankings. The final result was a matrix of 12 profiles made up 
of 10 attributes, each with two levels (‘yes’ or ‘no’)(Table 3). 
Ranking exercise and analysis 
An online form, with a file including the 12 profiles, was created and circulated to 
participants. The materials included an explanation of the exercise, description of the profiles 
and table for the participant to complete with their results. Copies of the materials are 
included in Appendix A and B. We used the conjoint analysis function within SPSS 
software19-22 consistent with previous studies17,18.  
Qualitative discussion 
A EU-TOPIA project workshop was held in Budapest in September 2017 to which 
respondents of the survey were invited. During the workshop, a facilitated group discussion 
of an hour duration was held with a selection of respondents.  We explored whether 
respondents were surprised at the results of the survey, whether they believed that all 
important attributes had been included, and discussed the respondents’ response to the 
conjoint ranking methodology.  
Results 
Sample characteristics 
The sample included 66 participants from 31 countries taking part in the EU-TOPIA 
workshop. Respondents were mainly from cancer screening organisations, researchers or 
policy-makers, whose more specific roles are shown in Figure 2 (11 did not specify their 
role). 
Importance scores 
The results of the experiment are shown in Figure 3 and Table 4.  There was a noticeable 
division of results between the four most important attributes, all with an average importance 
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factor of over 15 and the other six attributes which had an importance factor of less than 
seven. 
Follow-up workshop with respondents 
Methods such as this, by forcing trade-offs, can reveal preferences that would otherwise 
remain concealed. In the workshop discussion, participants were reluctant to accept that 
they had rated quality assurance as of low importance and were surprised at this result. We 
explored several explanations for the difference between the results of the experiment and 
the group opinion with them. One explanation was that some of the attributes are sequential. 
For example, guidelines can only be adhered to once in place and quality can only be 
assured once other attributes are developed (e.g. monitoring) so those ranking profiles in the 
experiment may have taken this into account implicitly. Another explanation, although less 
intuitive, was that guidelines are considered more wide-ranging than quality assurance and 
therefore ranked higher by respondents aiming to maximise their choice. Knowledge of the 
attributes in practice may also have influenced ranking in the experiment. For example, the 
group indicated that actual guidelines are sometimes based on expert opinion rather than 
higher-level evidence and are infrequently updated. Therefore, this issue should be 
prioritized as a key factor among others. Knowledge of this may affect how important this 
factor is in an effective screening programme.  
Discussion 
Strengths and limitations of the study 
So far, much of the literature on cancer screening has focused on those elements within the 
organisational boundaries of organised programmes. Yet, to achieve optimal outcomes, it 
can be argued that it is necessary to look more widely. This experiment suggests that those 
involved in the operation of cancer screening agree with our applied concept. We are 
unaware of a similar exercise being undertaken previously. Based on this experience we 
also suggest that performance indicators for cancer screening programmes2 should take a 
broader perspective in assessing effectiveness. 
The study used an established methodology for conjoint analysis20-22. The list of attributes 
used in the study was formulated in several phases, including data collection (from the 
literature), data reduction, removing inappropriate attributes and wording (refined as a result 
of the pilot and reviewed by experts) in line with recommendations in the literature26. The trial 
phase with healthcare researchers and review by experts ensured external validity. In a 
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follow-up phase, the results were validated with respondents in a qualitative manner which 
also allowed a better understanding of the quantitative results. The selected sample included 
experts on cancer screening programmes throughout Europe, with coverage of 31 countries.  
The main limitation of the study was the sample size. Ideally, the sample size would have 
been larger27. However, the addition of a qualitative phase allowed us to use the quantitative 
results as a source for discussion and future actions. In addition, the sample focused on 
researchers, organisers of screening programmes and policy makers. A more extensive 
study might have included service providers, health professionals directly involved in the 
screening process, and people invited for screening. Previous research has shown that 
patient preferences, as perceived by healthcare professionals, may differ from those of the 
patients themselves28 so a comprehensive sample including all stakeholders would increase 
the robustness of any study.  
The post-experiment discussion with respondents suggested some disagreement with the 
results of the experiment. Previous research in cancer screening has also shown differences 
when comparing the results of choice experiments versus ordinary rating, ranking or survey 
questions29,30, even if overall there was agreement with the attribute ranked as most 
important ones29. However, discussion at the workshop indicated that some attributes were 
inter-related, sequential or more wide-ranging and this might have affected how people 
ranked the profiles. For example, without implemented evidence based guidelines, assuring 
quality would not be feasible. Conversely, assuring quality may make the assumption that 
guidelines and a screening organisation have already been established. This may explain 
the low score for the quality assurance attribute.  
Comparison with the literature 
As previously mentioned, previous conjoint studies have been conducted with cancer 
screening programmes but the focus has generally been on understanding patient 
preferences9,10,31-36 or, on occasion, physicians28, to inform strategies to increase uptake. For 
example, discrete choice experiments have investigated patient preferences for the test 
options made available30,37, test intervals37, travel time30, and financial incentives or co-
payments30 Other studies have also investigated the impact of including labels for specific 
screening tests versus non-labelling of a list of attributes38. In a review of the literature on 
breast, cervical and colorectal cancer screening9, of 22 included studies on patient 
preferences, 15 assessed test attributes, two studies assessed healthcare delivery, and five 
studies included both. Test attributes had a significant effect on choice of test and healthcare 
delivery (how screening is organised) had a mixed effect. This review recommended further 
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research on barriers to uptake, particularly research including healthcare delivery, as this 
study aims to do. Another systematic review of colorectal cancer screening10 showed that 
people preferred screening to non-screening and were willing to trade-off complications to 
get more clinical benefit. A similar review of 28 cancer treatment preference studies39 found 
that most attributes related to outcomes (70%) while process and cost attributes only related 
to 25% and 5% of evidence respectively, showing less attribute importance as well as being 
less often included in studies.   
Implications  
There is a lack of evidence on the priorities of policy makers who are forced to make trade-
offs in cancer screening. Discrete choice methods can be used to evaluate healthcare 
interventions, services and policies including both outcomes and process attributes40,41, 
including priority setting42. As previously mentioned, when looking at patient preferences, 
factors such as convenience (mode of administration and location of treatment) may overlap 
with health service design. However, choice experiments can also be used to examine 
health system and service attributes. In previous studies discrete choice has been used: 1) 
to assess the views of policymakers on health technology assessment43, 2) to assess 
decision making criteria by policy makers in five countries, including efficiency and equity44, 
3) to explore reforms to payment systems45 4) to assess pharmacy services46 and 5) to 
inform health workforce policy47. These studies have demonstrated the value of choice 
experiments in designing health services. However, none of these studies have addressed 
cancer screening directly.  
Conclusion 
This choice experiment concluded that having up-to-date and evidence-based guidelines 
was the most important factor in an effective screening programme, followed by 
systematically monitoring screening uptake, having a population register covering all the 
eligible population and monitoring long-term outcomes. When required to trade-off, 
respondents selected these attributes rather than quality assurance or guideline adherence. 
The follow-up qualitative research on these priorities suggests that quality assurance and 
guideline adherence are also important to them. However, the main contribution of this 
exercise was to stimulate a valuable discussion on the role of quality assurance and 
guidelines that might otherwise not have happened, and which allowed some important 
issues to emerge. The factors that were deemed most important in the choice experiment 
may be the most important ones to have in the first place, with quality assurance dependent 
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upon them. This suggests that, where resources are limited, establishing evidence-based 
and up-to-date guidelines should be a priority, followed by monitoring uptake, and ensuring a 
comprehensive population register before developing other aspects of the screening 
programme. However, a more comprehensive study, including a wider group of stakeholders 
and a more extensive list of independent attributes would provide even more additional 
insights. 
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Cancer screening in Europe 
 
Thank you for participating in this exercise to understand which elements of a cancer screening 
program are most important. You will have received, separately, a list of profiles of possible cancer 
screening programs. Each differs in certain ways. We would like you to read them, and then place 
them in order, deciding which you feel is "best". We do not have any fixed view as to what "best" 
means because we know that each of you may place a higher value on some aspects rather than 
others. Indeed, that is what we are trying to discover.  
 
This exercise is part of the EUTOPIA project, a Horizon 2020 project led by Erasmus MC, Rotterdam, 
and this part is led by the London School of Hygiene and Tropical Medicine.  
 
Please complete the following table, ranking each profile of a screening programme in order. Each of 
the profiles has a number. Please rank the programme that you think is the "best", according to your 
judgement as first. The next "best" should be ranked second, and so on, until you have ranked them 
all in order. It is not permitted to rank any as equal. You will need to scroll right using the bar at the 
bottom to see all the profiles. * 
 
Profile 1 2 3 4 5 6 7 8 9 10 11 12 
             
Best ⃝ ⃝ ⃝ ⃝ ⃝ ⃝ ⃝ ⃝ ⃝ ⃝ ⃝ ⃝ 
Second 
best 
⃝ ⃝ ⃝ ⃝ ⃝ ⃝ ⃝ ⃝ ⃝ ⃝ ⃝ ⃝ 
Third 
best 
⃝ ⃝ ⃝ ⃝ ⃝ ⃝ ⃝ ⃝ ⃝ ⃝ ⃝ ⃝ 
Fourth 
best 
⃝ ⃝ ⃝ ⃝ ⃝ ⃝ ⃝ ⃝ ⃝ ⃝ ⃝ ⃝ 
5th best ⃝ ⃝ ⃝ ⃝ ⃝ ⃝ ⃝ ⃝ ⃝ ⃝ ⃝ ⃝ 
6th best ⃝ ⃝ ⃝ ⃝ ⃝ ⃝ ⃝ ⃝ ⃝ ⃝ ⃝ ⃝ 
7th best ⃝ ⃝ ⃝ ⃝ ⃝ ⃝ ⃝ ⃝ ⃝ ⃝ ⃝ ⃝ 
8th best ⃝ ⃝ ⃝ ⃝ ⃝ ⃝ ⃝ ⃝ ⃝ ⃝ ⃝ ⃝ 
9th best ⃝ ⃝ ⃝ ⃝ ⃝ ⃝ ⃝ ⃝ ⃝ ⃝ ⃝ ⃝ 
10th best ⃝ ⃝ ⃝ ⃝ ⃝ ⃝ ⃝ ⃝ ⃝ ⃝ ⃝ ⃝ 
11th best ⃝ ⃝ ⃝ ⃝ ⃝ ⃝ ⃝ ⃝ ⃝ ⃝ ⃝ ⃝ 
Worst ⃝ ⃝ ⃝ ⃝ ⃝ ⃝ ⃝ ⃝ ⃝ ⃝ ⃝ ⃝ 
 
Choice experiment: Please follow the instructions in the Google form. 
 
Choice Experiment – What Defines a Successful Cancer Screening Program? 
This document contains 12 profiles for use in a ‘Choice Experiment’1.  These profiles represent a series of cancer screening systems (for breast, cervical and 
colorectal cancer) with different attributes. These attributes represent characteristics of an effective screening program, based on the literature234.  Each profile 
includes a selection of elements of an effective screening programme (those attributes allocated a ‘yes’ in the profiles below).  Each profile includes a different 
combination of attributes. For example, profile 3 and profile 4 both include 5 attributes but the selection is different in the two profiles.  Following the instructions in 
the Google form, you will need to decide whether you think one selection of 5 attributes is better for a successful screening program than a different 5 attributes 
when putting all the 12 profiles in order from best to worst.  This is then repeated comparing other profiles.   
 
Cancer Screening 
Sub-system 
Short Description for 
Profile 
Full Description of Screening Programme Attribute 
Identification of 
population at risk 
Population register covers 
all eligible population 
Register used to identify population eligible for screening includes all people who require screening. 
Population register 
regularly updated 
Register used to identify population eligible for screening is regularly updated with changes of address, 
death and other eligibility criteria.   
Generation of 
knowledge and 
effectiveness 
National screening 
organisation established 
There is a well-defined national screening organisation responsible for assessing needs, evaluating the 
evidence and system design. 
Guidelines are up-to-date 
and evidence-based 
Guidelines for cancer screening are up-to-date and evidence-based. 
Maximisation of 
uptake (informed 
participation) 
Screening participation is 
systematically monitored 
The rate of informed participation is monitored and evaluated systematically, including monitoring equity of 
access to ensure everyone has the same opportunity to attend.  
Operation of the 
programme 
Quality assurance system 
in place 
A system to assure the quality of cancer screening is in place. 
Opportunistic screening is 
rare 
Parallel opportunistic screening outside of the population-based screening programme is rare as screening 
takes place within the organised program according to guidelines.  
Screening guidelines are 
adhered to 
Guidelines and protocols are adhered to by organisations, service providers and health professionals. 
Maximisation of 
follow-up 
Process for systematic 
follow-up in place 
There is a procedure and process for the systematic follow up of screen-detected lesions. 
Treatment Long term outcomes are 
monitored 
Monitoring of long term outcomes is established through a link between screening records and cancer 
registries. 
 
 
Choice experiment: Please follow the instructions in the Google form. 
 
 
 
Profile Number 1 
Card ID Population 
register 
covers all 
eligible 
population 
Population 
register 
regularly 
updated 
National 
screening 
organisation 
established 
Guidelines 
are up-to-
date and 
evidence-
based 
Screening 
participation 
is 
systematically 
monitored 
Quality 
assurance 
system in 
place 
Opportunistic 
screening is 
rare 
Screening 
guidelines 
are 
adhered to 
Process for 
systematic 
follow-up in 
place 
Long term 
outcomes 
are 
monitored 
1 Yes No Yes Yes No No Yes No No Yes 
 
 
Profile Number 2 
Card ID Population 
register 
covers all 
eligible 
population 
Population 
register 
regularly 
updated 
National 
screening 
organisation 
established 
Guidelines 
are up-to-
date and 
evidence-
based 
Screening 
participation 
is 
systematically 
monitored 
Quality 
assurance 
system in 
place 
Opportunistic 
screening is 
rare 
Screening 
guidelines 
are 
adhered to 
Process for 
systematic 
follow-up in 
place 
Long term 
outcomes 
are 
monitored 
2 Yes No No No Yes Yes No No Yes Yes 
 
 
Profile Number 3 
Card ID Population 
register 
covers all 
eligible 
population 
Population 
register 
regularly 
updated 
National 
screening 
organisation 
established 
Guidelines 
are up-to-
date and 
evidence-
based 
Screening 
participation 
is 
systematically 
monitored 
Quality 
assurance 
system in 
place 
Opportunistic 
screening is 
rare 
Screening 
guidelines 
are 
adhered to 
Process for 
systematic 
follow-up in 
place 
Long term 
outcomes 
are 
monitored 
3 No Yes No Yes Yes No Yes No Yes No 
Choice experiment: Please follow the instructions in the Google form. 
 
 
 
Profile Number 4 
Card ID Population 
register 
covers all 
eligible 
population 
Population 
register 
regularly 
updated 
National 
screening 
organisation 
established 
Guidelines 
are up-to-
date and 
evidence-
based 
Screening 
participation 
is 
systematically 
monitored 
Quality 
assurance 
system in 
place 
Opportunistic 
screening is 
rare 
Screening 
guidelines 
are 
adhered to 
Process for 
systematic 
follow-up in 
place 
Long term 
outcomes 
are 
monitored 
4 No Yes Yes No Yes No No Yes No Yes 
 
 
Profile Number 5 
Card ID Population 
register 
covers all 
eligible 
population 
Population 
register 
regularly 
updated 
National 
screening 
organisation 
established 
Guidelines 
are up-to-
date and 
evidence-
based 
Screening 
participation 
is 
systematically 
monitored 
Quality 
assurance 
system in 
place 
Opportunistic 
screening is 
rare 
Screening 
guidelines 
are 
adhered to 
Process for 
systematic 
follow-up in 
place 
Long term 
outcomes 
are 
monitored 
5 Yes Yes Yes No No No No No Yes No 
 
 
Profile Number 6 
Card ID Population 
register 
covers all 
eligible 
population 
Population 
register 
regularly 
updated 
National 
screening 
organisation 
established 
Guidelines 
are up-to-
date and 
evidence-
based 
Screening 
participation 
is 
systematically 
monitored 
Quality 
assurance 
system in 
place 
Opportunistic 
screening is 
rare 
Screening 
guidelines 
are 
adhered to 
Process for 
systematic 
follow-up in 
place 
Long term 
outcomes 
are 
monitored 
6 No No Yes No No Yes Yes Yes Yes No 
Choice experiment: Please follow the instructions in the Google form. 
 
 
 
Profile Number 7 
Card ID Population 
register 
covers all 
eligible 
population 
Population 
register 
regularly 
updated 
National 
screening 
organisation 
established 
Guidelines 
are up-to-
date and 
evidence-
based 
Screening 
participation 
is 
systematically 
monitored 
Quality 
assurance 
system in 
place 
Opportunistic 
screening is 
rare 
Screening 
guidelines 
are 
adhered to 
Process for 
systematic 
follow-up in 
place 
Long term 
outcomes 
are 
monitored 
7 No No Yes Yes Yes Yes No No No No 
 
 
Profile Number 8 
Card ID Population 
register 
covers all 
eligible 
population 
Population 
register 
regularly 
updated 
National 
screening 
organisation 
established 
Guidelines 
are up-to-
date and 
evidence-
based 
Screening 
participation 
is 
systematically 
monitored 
Quality 
assurance 
system in 
place 
Opportunistic 
screening is 
rare 
Screening 
guidelines 
are 
adhered to 
Process for 
systematic 
follow-up in 
place 
Long term 
outcomes 
are 
monitored 
8 Yes No No No Yes No Yes Yes No No 
 
 
Profile Number 9 
Card ID Population 
register 
covers all 
eligible 
population 
Population 
register 
regularly 
updated 
National 
screening 
organisation 
established 
Guidelines 
are up-to-
date and 
evidence-
based 
Screening 
participation 
is 
systematically 
monitored 
Quality 
assurance 
system in 
place 
Opportunistic 
screening is 
rare 
Screening 
guidelines 
are 
adhered to 
Process for 
systematic 
follow-up in 
place 
Long term 
outcomes 
are 
monitored 
9 No Yes No No No Yes Yes No No Yes 
Choice experiment: Please follow the instructions in the Google form. 
 
 
Profile Number 10 
Card ID Population 
register 
covers all 
eligible 
population 
Population 
register 
regularly 
updated 
National 
screening 
organisation 
established 
Guidelines 
are up-to-
date and 
evidence-
based 
Screening 
participation 
is 
systematically 
monitored 
Quality 
assurance 
system in 
place 
Opportunistic 
screening is 
rare 
Screening 
guidelines 
are 
adhered to 
Process for 
systematic 
follow-up in 
place 
Long term 
outcomes 
are 
monitored 
10 Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes 
 
 
Profile Number 11 
Card ID Population 
register 
covers all 
eligible 
population 
Population 
register 
regularly 
updated 
National 
screening 
organisation 
established 
Guidelines 
are up-to-
date and 
evidence-
based 
Screening 
participation 
is 
systematically 
monitored 
Quality 
assurance 
system in 
place 
Opportunistic 
screening is 
rare 
Screening 
guidelines 
are 
adhered to 
Process for 
systematic 
follow-up in 
place 
Long term 
outcomes 
are 
monitored 
11 No No No Yes No No No Yes Yes Yes 
 
 
Profile Number 12 
Card ID Population 
register 
covers all 
eligible 
population 
Population 
register 
regularly 
updated 
National 
screening 
organisation 
established 
Guidelines 
are up-to-
date and 
evidence-
based 
Screening 
participation 
is 
systematically 
monitored 
Quality 
assurance 
system in 
place 
Opportunistic 
screening is 
rare 
Screening 
guidelines 
are 
adhered 
to 
Process for 
systematic 
follow-up in 
place 
Long term 
outcomes 
are 
monitored 
12 Yes Yes No Yes No Yes No Yes No No 
 
Choice experiment: Please follow the instructions in the Google form. 
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Table 1:  Short description of attributes 
Cancer Screening Sub-system Short Description for Profile 
Identification of population at risk Population register covers all eligible population 
Population register regularly updated 
Generation of knowledge and effectiveness National screening organisation established 
Guidelines are up-to-date and evidence-based 
Informed participation Screening uptake is systematically monitored 
Operation of the programme Quality assurance system in place 
Opportunistic screening is rare 
Screening guidelines are adhered to 
Maximisation of follow-up Process for systematic follow-up in place 
Treatment Long term outcomes are monitored 
 
1 
 
Table 1:  Long description of attributes (added after pilot phase) 
Category Attribute 
Identification of population 
at risk 
Register used to identify population eligible for screening includes 
all people who require screening. 
Register used to identify population eligible for screening is 
regularly updated with changes of address, death and other criteria.   
Generation of knowledge 
and effectiveness 
There is a well-defined national screening organisation responsible for 
assessing needs, evaluating the evidence and system design. 
Guidelines for cancer screening are up-to-date and evidence-based. 
Maximisation of uptake The rate of informed participation is monitored and evaluated 
systematically, including monitoring equity of access to ensure everyone has 
the same opportunity to attend.  
Operation of the 
programme 
A system to assure the quality of screening is in place 
Parallel opportunistic screening outside of the population-based screening 
programme is not allowed to take place.  
Guidelines are adhered to 
Maximisation of follow up There is a procedure and process for the systematic follow up of screen-
detected lesions. 
Monitoring of long term outcomes is established through a link between 
screening records and cancer registries. 
 
1 
 
Table 1:  Profile matrix of attributes and levels generated by statistical software 
Card ID 
Population register covers all 
eligible population 
Population register regularly 
updated 
N
ational screening 
organisation established 
G
uidelines are up-to-date and 
evidence-based 
Screening participation is 
system
atically m
onitored 
Q
uality assurance system
 in 
place 
O
pportunistic screening is 
rare 
Screening guidelines are 
adhered to 
Process for system
atic follow
-
up in place 
Long term
 outcom
es are 
m
onitored 
1 Yes No Yes Yes No No Yes No No Yes 
2 Yes No No No Yes Yes No No Yes Yes 
3 No Yes No Yes Yes No Yes No Yes No 
4 No Yes Yes No Yes No No Yes No Yes 
5 Yes Yes Yes No No No No No Yes No 
6 No No Yes No No Yes Yes Yes Yes No 
7 No No Yes Yes Yes Yes No No No No 
8 Yes No No No Yes No Yes Yes No No 
9 No Yes No No No Yes Yes No No Yes 
10 Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes 
11 No No No Yes No No No Yes Yes Yes 
12 Yes Yes No Yes No Yes No Yes No No 
 
1 
 
Table 1:  Detailed breakdown of utility estimates and importance factors (n=66) 
Category Attribute Levels Utility 
Estimate  
Importance 
Factor  
Identification of 
population at risk 
Population register covers all eligible 
population 
Yes / No -.588 / .588 16.014 
Population register regularly updated Yes / No .255 / -.255 6.942 
Generation of 
knowledge and 
effectiveness 
National screening organisation 
established 
Yes / No -.232 / .232 6.323 
Guidelines are up-to-date and 
evidence-based 
Yes / No -.705 / .705 19.175 
Maximisation of uptake Screening uptake is systematically 
monitored 
Yes / No .664 / -.664 18.076 
Operation of the 
programme 
Quality assurance system in place Yes / No .073 / -.073 1.993 
Opportunistic screening is rare Yes / No -.210 / .210 5.704 
Screening guidelines are adhered to Yes / No -.164 / .164 4.467 
Maximisation of follow 
up 
Process for systematic follow-up in 
place 
Yes / No .215 / -.215 5.842 
Long term outcomes are monitored Yes / No -.568 / .568 15.464 
 
 
